Mytra (Itraconazole)

Itraconazole, the active ingredient in Mytra, is an azole antifungal presented as an oral formulation for oral use. It treats a range of superficial and systemic fungal infections in adults and children as prescribed.

GNH USA supplies Mytra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is used to manage fungal infections across several disease categories. - Superficial and systemic mycoses: eradicates the infecting fungus and resolves clinical symptoms. - Blastomycosis: eliminates Blastomyces dermatitidis organisms and prevents disease progression. - Histoplasmosis: clears Histoplasma capsulatum infection, especially in disseminated cases. - Aspergillosis: treats invasive Aspergillus species infections in immunocompromised patients. - Candidiasis: resolves Candida species infections of mucosal and systemic sites.

Itraconazole may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Rash: mild skin irritation or redness. - Elevated liver enzymes: mild, reversible changes in liver function tests.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Congestive heart failure: fluid retention and reduced cardiac function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photophobia. - Anaphylaxis: rare, life‑threatening allergic reaction. - QT prolongation: potential cardiac rhythm abnormalities.

Before initiating itraconazole therapy, consider the following safety measures. - Liver function: assess baseline hepatic enzymes and monitor periodically. - Cardiac status: evaluate for existing heart failure; avoid in decompensated cases. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Renal impairment: adjust dosing in severe kidney disease. - Store below 25°C: keep in the original pack, protect from moisture.

Itraconazole interacts with several drugs through metabolic pathways.

Major Interactions (Avoid): - Rifampicin: induces CYP3A4, markedly reducing itraconazole levels. - St. John’s wort: strong CYP3A4 inducer, may lead to therapeutic failure. - Certain antiarrhythmics (e.g., amiodarone): increase risk of cardiac toxicity.

Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin): may raise statin concentrations, monitor for myopathy. - Benzodiazepines (e.g., midazolam): increased sedation, adjust dose if needed. - Proton pump inhibitors: may reduce absorption, consider timing adjustments.